Manufacturing High-Potency Drugs Using Isolators - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Manufacturing High-Potency Drugs Using Isolators
The author discusses the key issues to consider when using isolators such as containment, protection of personnel, the efficiency of biodecontamination cycles, sterility assurance levels, barriers and their integrity, and environmental impact.

Pharmaceutical Technology


Isolators are the sole future of high-potency drug processing in the pharmaceutical industry. Isolators represent the only existing technology that guarantees the best protection for operators and the high sterility-assurance level of injectable products. The fully isolated system provides total containment for all material handling with the highest capital costs offset by lower operating cost.

Use of isolators has grown with the correspondent increase in the discovery and use of high-potency drugs. The industry is understanding the advantages of isolators even if regulations do not officially require their use. The isolator will be the only technology allowed by regulatory authorities for manufacturing high- potency drugs under safe conditions. The advantages offered by isolators compared with traditional cleanrooms is pushing the industry to choose isolator technology for future investments in high-potency manufacturing (1–10).

Maurizio Battistini is a general manager and the qualified person with Abraxis BioScience, via Cadepiano, 24–6917, Lugano Barbengo, Switzerland, tel. +41 91 9852640, Fax +41 91 9852641,

Note: A "qualified person" is a designation in European pharmaceutical regulations (Article, 51 EU Directive 2001/83/EC for Medicinal Products for Human Use).


1. FDA, Guidance for Industry—Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice Appendix 1: Aseptic Processing Isolators (Rockville, MD), Sept. 2004, available at, accessed Oct. 13, 2008.

2. FDA, Pharmaceutical CGMPS for the 21st Century—A Risk-based Approach (Rockville, MD), available at, accessed Oct. 13, 2008.

3. J. Lysford and M. Porter, "Barrier Isolation History and Trends," presented at the International Society for Pharmaceutical Engineering Washington Conference: Barrier Isolation Technology, Washington DC, June 2004.

4. ISO, ISO 14644-7 Cleanrooms and Associated Controlled Environments: Part Z: Separative Devices (Clean Air Hoods, Gloveboxes, Isolators and Mini Environments) (Geneva, Switzerland) Oct. 2004.

5. PDA, Technical Report No. 34 Design and Validation Of Isolator System for Manufacturing and Testing of Health Care Products, June 2001.

6. PIC/S, PI 014-1: Recommendation—Isolator Used for Aseptic Processing and Sterility Testing (Geneva, Switzerland), June 2002.

7. EUDRA, EU GMP: Eudra I: Medicinal Products for Human and Veterinary Use: Good Manufacturing Practices Vol. 4, Annex 1, p. 66.

8. "FDA Q&A on Barrier Isolation—The FDA Answers Your Questions on Barrier Isolator Technology," Pharm. Eng. 27 (2), 2007.

9. L. Francis, "Containment Considerations for Toxic and Potent Aseptic Liquid Filling," Pharm. Eng. 27 (3), 2007.

10. J. Agalloco, J. Akers, and R. Madsen, "Choosing Technologies for Aseptic Filling: Back to the Future, Forward to the Past, Pharm. Eng, 27 (1), 2007.

For a comparison of conventional cleanrooms, restricted access barrier systems, and isolators, see the online exclusive, "A Comparison of Conventional Cleanrooms, Restricted Access Barrier Systems and Isolators".


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here